Levetiracetam
Product Images NDC 14789-400

5 FDA label images from Nexus Pharmaceuticals Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 14789-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nexus Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Leveitracetam Structural Formula (Levetiracetam Injection Figure 1 Leveitracetam Structural Formula)

Leveitracetam Structural Formula (Levetiracetam Injection Figure 1 Leveitracetam Structural Formula)
Chemical structure of Levetiracetam depicted as a molecular diagram showing a pyrrolidone ring attached to an ethyl group and an amide functional group.*
FDA Label Image

Statistically Significant Versus Placebo (Levetiracetam Injection Figure 2 Statistically Significant Versus Placebo)

Statistically Significant Versus Placebo (Levetiracetam Injection Figure 2 Statistically Significant Versus Placebo)
A bar chart comparing the percentage of patients across three groups: Placebo (7.4%), KEPPRA 1000 mg/day (37.1%), and KEPPRA 3000 mg/day (39.6%). Each group includes the number of patients in parentheses (N=95 for Placebo, N=97 for KEPPRA 1000 mg/day, and N=101 for KEPPRA 3000 mg/day). An asterisk marks the KEPPRA bars, indicating statistical significance or relevance.*
FDA Label Image

Statistically Significant Versus Placebo (Levetiracetam Injection Figure 3 Table8 Statistically Significant Versus Placebo)

Statistically Significant Versus Placebo (Levetiracetam Injection Figure 3 Table8 Statistically Significant Versus Placebo)
A bar chart comparing the percentage of patients across three groups: Placebo, KEPPRa 1000 mg/day, and KEPPRa 2000 mg/day. The vertical axis shows the percentage of patients, with Placebo at 6.3%, KEPPRa 1000 mg/day at 20.8%, and KEPPRa 2000 mg/day at 35.2%. Sample sizes for each group are also indicated below the bars.*
FDA Label Image

Statistically Significant Versus Placebo (Levetiracetam Injection Figure 4 Figure3 Statistically Significant Versus Placebo)

Statistically Significant Versus Placebo (Levetiracetam Injection Figure 4 Figure3 Statistically Significant Versus Placebo)
A bar graph comparing the percentage of patients between two groups: Placebo (N=104) and KEPPRA 3000 mg/day (N=180). The Placebo group shows 14.4% of patients, while the KEPPRA 3000 mg/day group shows 39.4%, with an asterisk marking the KEPPRA bar.*
FDA Label Image

Levetiracetam Injection Box (Levetiracetam Injection Figure 5 Li Box)

Levetiracetam Injection Box (Levetiracetam Injection Figure 5 Li Box)
Levetiracetam Injection 500 mg/5 mL (100 mg/mL) carton, containing 10 single-use 5 mL vials. Labeled for intravenous use with a warning that it must be diluted prior to administration. The product is manufactured by Nexus Pharmaceuticals Inc and carries the NDC 14789-400-05.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.